Pharma News
FiercePharma is a respected source of coverage on the pharma industry. Find news on pharma companies like Johnson & Johnson, AstraZeneca and Novartis as well as the latest on FDA regulations, pharma layoffs, generic drugs, pharma marketing and more. For more information and analysis on these topics, please visit our biotechnology reports.
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Read more...
Mediator probe rolls on with searches at Afssaps, executives' homes
The Mediator scandal in France continues as investigators searched the offices of healthcare regulators Afssaps and the homes of several of its executives. The agency faced a public outcry over its Read more...
FDA talks, but doctors don't necessarily listen
Poor FDA. It takes flak every time a drug spawns unexpected side effects. But when it tries to warn doctors about those side effects--and offers advice for preventing them--few physicians are Read more...
Gloom for the pharma industry, yes. Doom? No
AstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate Read more...
Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarter
Another day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for Read more...
As blockbuster drugs fade, so does TV advertising
The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007 Read more...
Novo amps up 2012 expectations on strong Victoza sales
Novo Nordisk ($NVO) boosted its sales outlook for 2012 after sales of the diabetes drug Victoza more than doubled to 2.1 billion crowns, beating analyst estimates. It's counting on new long-acting Read more...
Novartis investor group urges vote against Vasella's pay
Daniel Vasella (photo) is wearing a bulls-eye again. The Novartis ($NVS) chairman is drawing fire for collecting a multimillion-dollar compensation package, just a few months after activists Read more...
GSK resolves 20K more Avandia lawsuits, lawyer says
GlaxoSmithKline ($GSK) has reached a deal to settle another 20,000 lawsuits over its diabetes drug Avandia, a lawyer for the plaintiffs told Bloomberg. The settlement came out of court-ordered Read more...
Merck's diabetes drugs offset Remicade sales decline
Merck ($MRK) managed to beat analyst estimates for fourth-quarter profits and supply slight sales growth of 2%. That's saying something during a quarter when some drugmakers saw profits drop by half Read more...
NICE rejects J&J's Zytiga as too expensive
The U.K.'s cost-effectiveness gatekeepers want to shut out Johnson & Johnson's ($JNJ) new prostate cancer pill. The National Institute for Health and Clinical Excellence issued draft guidance Read more...
AstraZeneca puts 7,300 jobs on the chopping block
The analyst talk was almost half right. AstraZeneca ($AZN) is sharpening its jobs ax for a new round of layoffs. But the number of jobs to be cut isn't 3,000. It's 7,300. Half of the cuts will hit Read more...
Vertex backs up pricey new CF drug with co-pay help
Vertex Pharmaceuticals ($VRTX) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's cause instead of Read more...
FDA's new-drug approvals of 2011
2011 was a big year for drugmakers seeking to get their innovative products approved, as the FDA blessed 30 new drugs, a 7-year high. Among the lucky ones were Johnson & Johnson ($JNJ) and Read more...
Roche results spotlight targeted-drug strategy
After a series of Big Pharma letdowns, Roche's ($RHHBY) results announcement was a series of positives: An increase in 2011 net income, a sales-growth forecast in the "low to mid-single digits," and Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
